Liquid Biopsy Market Research to Reach USD 27.42 Billion by 2035 as Cancer Blood Tests, AI Diagnostics and Precision Oncology Advance
Ottawa, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The global liquid biopsy market is projected to grow from USD 7.08 billion in 2025 to USD 27.42 billion by 2035, expanding at a compound annual growth rate (CAGR) of 14.5% from 2026 to 2035. At the same time, new regulatory developments, advances in circulating tumor DNA analysis, and growing pharmaceutical partnerships are reshaping the competitive landscape for cancer diagnostics. Towards Healthcare's market research identifies North America as the leading region and Asia Pacific as the fastest-growing market with next-generation sequencing, circulating nucleic acids, and therapy selection among the sector's major areas of activity.
Download a sample: Liquid Biopsy Market Report Sample to review the report's coverage and research scope.
Market Data Snapshot
Market estimates and forecasts: Towards Healthcare's Liquid Biopsy Market report, updated September 10, 2026. Regional and country estimates should be interpreted within the report's stated market definitions.
What the Latest Market Data Shows
Liquid biopsy is moving beyond a niche alternative to tissue biopsy. The technology analyzes biomarkers including circulating tumor DNA (ctDNA), circulating tumor cells, RNA, and other molecular signals from blood and selected other body fluids. Its commercial value lies in enabling molecular profiling, therapy selection, treatment monitoring, and detection of residual or recurring disease without requiring a conventional tissue sample in every case.
The market's projected expansion reflects several overlapping demand pools: precision oncology, targeted cancer therapies, molecular monitoring, and the development of blood-based screening tests. These applications have different evidence requirements and commercial pathways, meaning companies need to assess them separately rather than treating all liquid biopsy products as interchangeable.
The U.S. liquid biopsy market alone is projected to increase from USD 2.78 billion in 2026 to USD 8.90 billion by 2035, at a CAGR of 13.82%. That outlook makes regulatory authorization, reimbursement, clinical utility, and relationships with pharmaceutical developers important competitive factors for diagnostic businesses.
Schedule a meeting: Connect with our expert team to discuss your requirements.
Segment trends and their commercial implications
Segment positions and outlooks are based on Towards Healthcare's published market analysis.
The key strategic distinction is between tests used to guide treatment in patients with known cancer and tests intended to screen apparently healthy populations. Therapy-selection assays can be tied to specific treatment decisions and companion diagnostic pathways. Multi-cancer early-detection tests, by contrast, must demonstrate how their results should guide follow-up, how false positives and false negatives are managed, and whether screening improves meaningful health outcomes.
For manufacturers and investors, this distinction affects clinical-development priorities, product positioning, pricing assumptions, reimbursement planning, and the evidence required before scaling commercial deployment.
Latest Liquid Biopsy Industry News and Company Developments
The strongest competitive signals in 2026 are coming from companion diagnostics, minimal residual disease (MRD) testing, multi-cancer early detection, and expanding reimbursement. These developments show how commercial success increasingly depends on evidence, regulatory status, and access not just the ability to identify cancer-associated biomarkers.
1. Guardant Health expands companion diagnostic capabilities
On October 8, 2026, Guardant Health announced European approval of Guardant360 CDx as a companion diagnostic for AstraZeneca's camizestrant in advanced estrogen receptor-positive breast cancer. The development strengthens the connection between liquid biopsy testing and targeted treatment decisions.
In May 2026, the U.S. FDA also approved an expanded version of Guardant360 Liquid CDx, integrating genomic and epigenomic insights and assessing a genomic footprint 100 times wider than the previously approved version. The expansion illustrates the competitive value of broader molecular profiling and the potential to support additional treatment decisions.
For pharmaceutical companies, this creates opportunities to evaluate companion diagnostic partnerships earlier in drug development. For diagnostic developers, it increases the importance of assay validation, biomarker coverage, regulatory submissions, and integration into oncology treatment pathways.
2. Grail's Galleri advances toward a potential regulatory milestone
In September 2026, an FDA advisory panel voted 7–2 that the potential benefits of Grail's Galleri multi-cancer early-detection blood test outweighed its risks. The test is designed to identify signals associated with more than 50 cancer types from a blood sample.
However, the advisory decision is not an FDA marketing approval. Questions remain about sensitivity, false-positive results, detection of early-stage cancers, follow-up procedures, and evidence of improved patient outcomes. The distinction is commercially important: a favorable advisory vote can improve a product's regulatory outlook without guaranteeing approval, reimbursement, or widespread adoption.
Companies developing multi-cancer early-detection tests should therefore track clinical performance, confirmatory testing pathways, healthcare-provider acceptance, regulatory milestones, and payer decisions together.
3. MRD testing gains further access and clinical momentum
Quest Diagnostics announced in June 2026 that its Haystack MRD circulating tumor DNA test had received New York State approval, broadening access to testing for residual or recurring disease in solid-tumor cancers. The company stated that the test was then authorized for patient testing in all 50 U.S. states.
Meanwhile, Natera's Signatera received Japanese regulatory approval for adjuvant colorectal cancer applications in 2026, and expanded guideline recognition has supported interest in ctDNA-based MRD testing across selected cancer settings.
These developments make MRD testing a strategically important area for monitoring cancer recurrence and treatment response. They also highlight the need to distinguish regulatory clearance, clinical guideline inclusion, reimbursement coverage, and demonstrated clinical utility four different factors that affect market adoption.
Explore further insights: Visit the Liquid Biopsy Market report for market forecasts, segment analysis, regional intelligence, and company coverage.
Company intelligence snapshot
The competitive implication is clear: liquid biopsy providers are pursuing distinct commercial strategies. Some are focusing on treatment selection and companion diagnostics; others are building MRD monitoring portfolios or pursuing multi-cancer screening. Investors and business-development teams need to benchmark these strategies separately.
Where the Next Market Opportunities Are Emerging
Companion diagnostics and precision oncology
Liquid biopsy can help identify molecular alterations relevant to targeted therapies when tissue testing is unavailable, insufficient, or difficult to obtain. Pharmaceutical companies can use these capabilities to support clinical trial enrollment, biomarker stratification, and companion diagnostic development.
The opportunity for diagnostic businesses is to establish partnerships around specific drug-development programs and cancer indications rather than relying exclusively on broad testing portfolios.
Multi-cancer early detection
Blood-based screening tests could expand the addressable population beyond patients already diagnosed with cancer. However, commercial opportunity depends on demonstrating clinical value, managing false-positive and false-negative results, establishing confirmatory diagnostic pathways, and securing payer coverage.
Businesses should evaluate these requirements before using potential screening populations to build revenue forecasts.
Asia Pacific expansion
Asia Pacific is projected to be the fastest-growing regional market. China, Japan, India, South Korea, and Australia offer different combinations of healthcare infrastructure, oncology research, diagnostic capabilities, reimbursement environments, and patient access.
Companies considering regional expansion should compare country-level demand, laboratory capabilities, regulatory requirements, distribution networks, local partnerships, and test affordability before committing resources.
AI-enabled molecular analysis
AI and computational biology can support biomarker identification, signal interpretation, and analysis of complex molecular datasets. Their commercial contribution depends on analytical validation, reproducibility, integration into laboratory workflows, and evidence that improved interpretation translates into meaningful clinical utility.
Reagents, laboratory services, and manufacturing
The projected growth of kits and reagents creates opportunities for recurring revenue, while increased testing volumes can support laboratory automation, sample-processing technologies, sequencing workflows, and specialized diagnostic services.
Suppliers should monitor instrument compatibility, reagent demand, production scalability, quality requirements, and laboratory purchasing criteria.
Risks and Challenges Companies Should Monitor
The market's growth potential does not eliminate commercial and clinical uncertainty. Key issues include:
These factors should be incorporated into product prioritization, investment assessments, market-entry planning, and commercial forecasts.
How Towards Healthcare Helps Companies Navigate the Liquid Biopsy Market
Towards Healthcare Research & Consulting supports pharmaceutical companies, biotechnology developers, diagnostic manufacturers, laboratories, investors, and suppliers with market-specific intelligence that connects industry developments to business decisions.
Master Dataset and competitive intelligence
A liquid biopsy dataset can bring together information on diagnostic companies, assay portfolios, biomarker types, cancer indications, testing platforms, clinical applications, commercial partnerships, and geographic presence.
Business-development teams can use this information to identify potential pharmaceutical partners, clinical research collaborators, laboratory customers, and regional distributors. Investors can compare company portfolios and development stages, while manufacturers can assess demand opportunities for reagents, instruments, and associated services.
Towards Healthcare Quadrant
The quadrant framework can support comparisons based on technology capabilities, product breadth, clinical applications, partnerships, geographic presence, and strategic development. It helps decision makers identify competitors, assess differentiation, and evaluate potential collaboration or acquisition targets.
Interactive Dashboard and ongoing intelligence
An interactive dashboard can bring together market indicators, company announcements, product developments, clinical milestones, regulatory decisions, reimbursement changes, and regional expansion activity.
This enables commercial, strategy, and business-development teams to monitor a changing market and evaluate how individual developments may affect their priorities.
Customized research
Projects can address specific business questions, including:
Market intelligence can be updated monthly, quarterly, every six months, or annually, depending on client requirements. Monthly tracking is particularly relevant for regulatory decisions, product launches, clinical developments, partnerships, and reimbursement changes, while quarterly and annual reviews can support commercial planning and investment decisions.
Access Liquid Biopsy Market Intelligence
Related Reports
Partner
Connect With Us
Follow Towards Healthcare
For relevant samples, case studies, and examples, fill out the form on the Towards Healthcare website or contact the expert team at sales@towardshealthcare.com.